Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma, T-Cell: early-phase trial registry
7 of 10 indexed Lymphoma, T-Cell trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 7 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Lymphoma, T-Cell: 10 US clinical trials tracked, 7 recruiting.
Lymphoma, T-Cell is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Jonathan Brammer, running 1 of these trials.
Enrollment posture brief
Registry condition lymphoma-t-cell
OPEN 7 | RECR 70% | LATE 1 | EARLY 9 | RANK #1724 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)
Lymphoma, T-Cell lists 7 open slots (70% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma, T-Cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma, T-Cell is recruiting above its size-band peers.
7 of 10 indexed trials (70%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoma, T-Cell trials is spread across many organizations.
Jonathan Brammer accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Lymphoma, T-Cell enrolment sits around 148 participants.
Median target enrolment is 148 among the 10 trials that report a genuine target (sentinel values excluded). 5 of those (50%) plan for fewer than 100 participants.
-
Lymphoma, T-Cell research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT04104776
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Step Pharma, SAS
NCT05463263
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals
NCT06561048
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
University of Virginia
NCT03161223
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT05476770
MB-105 in Patients With CD5 Positive T-cell Lymphoma
March Biosciences
NCT06534060
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Jonathan Brammer
NCT07356245
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Innate Pharma
NCT03902184
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT05540340
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Pfizer
NCT00043368
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma, T-Cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma, T-Cell trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma, T-Cell page
10 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Lymphoma, T-Cell trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jonathan Brammer sponsors the most Lymphoma, T-Cell trials on record, review their full trial history before evaluating a specific study. See Jonathan Brammer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma, T-Cell condition card totals 10 registered trials; most-linked intervention Pralatrexate; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.